Synlogic, Inc. (SYBX)
NASDAQ: SYBX · IEX Real-Time Price · USD
1.840
-0.020 (-1.08%)
May 3, 2024, 4:30 PM EDT - Market closed
Synlogic Revenue
In the year 2023, Synlogic had annual revenue of $3.37M with 185.68% growth. Revenue in the quarter ending December 31, 2023 was $2.77M with 2,512.26% year-over-year growth.
Revenue (ttm)
$3.37M
Revenue Growth
+185.68%
P/S Ratio
6.35
Revenue / Employee
$561,833
Employees
6
Market Cap
21.39M USD
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 3.37M | 2.19M | 185.68% |
| Dec 31, 2022 | 1.18M | -574.00K | -32.73% |
| Dec 31, 2021 | 1.75M | 1.21M | 221.83% |
| Dec 31, 2020 | 545.00K | -1.68M | -75.49% |
| Dec 31, 2019 | 2.22M | -296.00K | -11.75% |
| Dec 31, 2018 | 2.52M | 76.00K | 3.11% |
| Dec 31, 2017 | 2.44M | 2.00M | 450.45% |
| Dec 31, 2016 | 444.00K | - | - |
| Dec 31, 2015 | 0 | - | - |
| Dec 31, 2014 | 0 | - | - |
| Dec 31, 2013 | 0 | - | - |
| Dec 31, 2012 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Cue Health | 70.94M |
| DermTech | 15.30M |
| NeurAxis | 2.46M |
| TherapeuticsMD | 1.30M |
| Aptorum Group | 431.38K |
| Serina Therapeutics | 142.00K |
| Alaunos Therapeutics | 5.00K |
SYBX News
- 6 weeks ago - Synlogic Reports Fourth Quarter and Full Year 2023 Financial Results - GlobeNewsWire
- 2 months ago - Synlogic Adopts Limited Duration Stockholders Rights Plan - GlobeNewsWire
- 3 months ago - Synlogic Announces Decision to Discontinue Synpheny-3 Study and Provides Corporate Update - GlobeNewsWire
- 3 months ago - Synlogic Announces Publication of Preclinical and Clinical Data for SYNB1353 as a Potential Treatment for Classical Homocystinuria - GlobeNewsWire
- 4 months ago - Synlogic Provides Corporate Update and Outlook for 2024 - GlobeNewsWire
- 4 months ago - Synlogic Announces Contract with the Air Force Research Lab - GlobeNewsWire
- 5 months ago - Synlogic Announces Abstract Accepted for Poster Presentation at the International Conference on Microbiome Engineering 2023 - GlobeNewsWire
- 6 months ago - Synlogic Reports Third Quarter 2023 Financial Results and Provides Corporate Update - GlobeNewsWire